Drug Trial Radar · NCT05306340
A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With the Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer)
Last checked: Nov 19, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
373
Actual
Start
Aug 3, 2022
Primary completion
Jul 16, 2025
Study completion Jun 15, 2027
Sponsor
- Lead sponsor
- Genentech, Inc.Roche (Genentech) (RHHBY)
- Sponsor type
- Industry
- First posted
- Apr 1, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This Phase III, randomized, open-label, multicenter study will evaluate the efficacy and safety of giredestrant plus everolimus compared with the physician's choice of endocrine therapy plus everolimus in participants with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer who have had previous treatment with cyclin-dependent kinase 4/6 inhibitors (CDK4/6is) and endocrine therapy, either in the locally advanced/metastatic or the adjuvant setting.
Conditions
- Estrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast Cancer
Interventions
GiredestrantDrug
Participants will receive treatment with giredestrant 30 milligrams (mg) orally once a day (QD) on Days 1-28 of each 28-day cycle until unacceptable toxicity or disease progression as determined by the investigator according to Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST v1.1).
ExemestaneDrug
If exemestane is chosen as the physician's choice of endocrine therapy, the participant will receive exemestane at a dose of 25 mg orally once a day (QD) on Days 1-28 of each 28-day cycle or as per local label, until unacceptable toxicity or disease progression as determined by investigator according to RECIST v1.1.
FulvestrantDrug
If fulvestrant is chosen as the physician's choice of endocrine therapy, the participant will receive fulvestrant in the clinic at a dose of 500 mg intramuscularly on Day 1 and Day 15 of Cycle 1, then Day 1 of each cycle thereafter (1 cycle is 28 days) or as per local prescribing information, until unacceptable toxicity or disease progression as determined by investigator according to RECIST v1.1.
TamoxifenDrug
If tamoxifen is chosen as the physician's choice of endocrine therapy, the participant will receive tamoxifen at a dose of 20 mg orally QD on Days 1-28 of each 28-day cycle or as per local prescribing information, until unacceptable toxicity or disease progression as determined by investigator according to RECIST v1.1.
EverolimusDrug
Participants will receive treatment with everolimus 10 mg orally QD during each 28-day cycle until unacceptable toxicity or disease progression as determined by the investigator according to RECIST v1.1.
LHRH AgonistDrug
Only premenopausal/perimenopausal female participants and male participants will receive a luteinizing hormone-releasing hormone (LHRH) agonist on Day 1 of each 28-day treatment cycle. The investigator will determine and supply the appropriate LHRH agonist locally approved for use in breast cancer.
Dexamethasone Mouth RinseDrug
A compounded alcohol-free mouthwash of dexamethasone (0.5 mg in 5 mL) will be supplied, where feasible. It is strongly recommended for prophylaxis or treatment of stomatitis/mucositis. Participants should use the alcohol-free mouthwash of dexamethasone four times QD for 8 weeks started concurrently with study treatment, and use it reactively thereafter with the first appearance of symptoms.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-Free Survival, as Determined by the Investigator According to RECIST v1.1, in the ESR1m Subpopulation and ITT PopulationTime frame: From randomization until the first occurrence of disease progression or death from any cause, whichever occurs first (up to 42 months)
Locations
136 sites in 13 countries. Site status is shown where the registry gives one.
Alaska Oncology & Hematology, LLC
Anchorage, Alaska
Arizona Oncology Associates, PC-CASA
Tucson, Arizona
University of Arkansas for Medical Sciences
Little Rock, Arkansas
Alta Bates Summit Medical Center
Berkeley, California
Beverly Hills Cancer Center
Beverly Hills, California
TOI Clinical Research
Cerritos, California
Women's Cancer Care
Fresno, California
Scripps Health
La Jolla, California
Los Angeles Hematology Oncology Medical Group
Los Angeles, California
University of California, Irvine Medical Center
Orange, California
Yale Cancer Center
New Haven, Connecticut
Mount Sinai Medical Center
Miami Beach, Florida
Orlando Health Cancer Institute
Orlando, Florida
Northwest Georgia Oncology Centers PC - Marietta
Marietta, Georgia
Summit Cancer Care PC
Savannah, Georgia
Northwestern University
Chicago, Illinois
Springfield Clinic
Springfield, Illinois
Indiana University Melvin and Bren Simon Cancer Center
Indianapolis, Indiana
University of Kansas Cancer Center
Westwood, Kansas
Eastern Maine Medical Center
Brewer, Maine
New England Cancer Specialists
Scarborough, Maine
Anne Arundel Medical Center
Annapolis, Maryland
University of Maryland Greenebaum Cancer Center
Baltimore, Maryland
Mercy Medical Center
Baltimore, Maryland
Dana Farber Cancer Institute
Boston, Massachusetts
Metro-Minnesota Community Oncology Research Consortium
Saint Louis Park, Minnesota
Oncology Hematology West, PC dba Nebraska Cancer Specialists
Omaha, Nebraska
Renown Regional Medical Center
Reno, Nevada
Memorial Sloan Kettering - Basking Ridge
Basking Ridge, New Jersey
Memorial Sloan Kettering - Monmouth
Middletown, New Jersey
San Juan Oncology Associates
Farmington, New Mexico
The Blavatnik Family ? Chelsea Medical Center at Mount Sinai
New York, New York
Icahn School of Medicine at Mount Sinai
New York, New York
Memorial Sloan-Kettering Cancer Center
New York, New York
Stony Brook University Medical Center
Stony Brook, New York
SCRI Mark H. Zangmeister Center
Columbus, Ohio
Oklahoma Cancer Specialists and Research Institute
Tulsa, Oklahoma
St Charles Medical Center Bend
Bend, Oregon
Abramson Cancer Center
Philadelphia, Pennsylvania
UPMC Hillman Cancer Center - Magee-Women?s Hospital
Pittsburgh, Pennsylvania
Showing 40 of 136 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.